Antitachycardia pacing for reduction of implantable cardioverter-defibrillator shocks

Abstract

Antitachycardia pacing (ATP) strategies represent safe, effective, and painless therapy for ventricular tachyarrhythmias, with a large body of clinical evidence supporting their routine use in both primary and secondary implantable cardioverter-defibrillator recipients. This article details the evidence supporting the use of standardized and validated ATP strategies for primary prevention patients and the conceptual framework to design effective ATP strategy for secondary prevention patients.

Keywords: Antitachycardia pacing; Implantable cardioverter-defibrillator; Sudden cardiac death.